A5077840773- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Renal cell carcinoma treatment
- Traffic Prediction and Management Techniques
- Colorectal Cancer Screening and Detection
- Multiple and Secondary Primary Cancers
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Global Cancer Incidence and Screening
- Renal and related cancers
- Esophageal Cancer Research and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Bone health and treatments
- Clinical practice guidelines implementation
- Genital Health and Disease
- Pelvic floor disorders treatments
- Urinary Tract Infections Management
- Cancer, Hypoxia, and Metabolism
- Urologic and reproductive health conditions
Kagawa University
2016-2025
Kagawa University Hospital
2019-2025
Takamatsu University
2019-2022
Kindai University
2022
Suzuki (Japan)
2018
Université Paris-Est Créteil
2007
City Hospital
2005
Sakai Municipal Hospital
2003-2005
University of Toyama
2005
Tokyo Metropolitan Police Department
2003
BACKGROUND: Preclinical studies and results of a phase 2 trial abiraterone olaparib suggest combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor is with next-generation hormonal agent to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted double-blind, 3 versus placebo in patients mCRPC first-line setting. Patients were enrolled regardless homologous recombination repair gene mutation (HRRm) status. HRRm status was...
11 Background: Preclinical studies have shown combined anti-tumor effect through interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor signaling pathways. A Phase II trial (NCT01972217) in pts with mCRPC unselected by homologous recombination repair (HRR) status who previously received docetaxel demonstrated improved radiographic progression-free survival (rPFS) for treated ola + abi vs pbo (Clarke N, 2018). The III PROpel study (NCT03732820) evaluates the...
Abstract These guidelines cover a wide range of topics from prostate cancer epidemiology to palliative care. Questions arising in daily clinical practice have been extracted and formulated as questions. In the 4 years since previous edition, there major changes – for example, robot‐assisted prostatectomy has rapidly come into widespread use, new hormones anticancer drugs developed castration‐resistant cancer. response these developments, number fields included this guideline was increased 11...
LBA16 Background: PROpel (NCT03732820) met its primary endpoint showing significant investigator-assessed radiographic progression-free survival (rPFS) benefit for patients with mCRPC treated abi + ola vs pbo in the 1L setting (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54–0.81, P< 0.001, data cut-off: 7/30/2021). Sensitivity analysis by blinded independent central review was consistent. A trend toward OS observed at time of rPFS (28.6% maturity, HR 0.86, CI 0.66–1.12) and a...
This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under leadership Urological Association, with members selected from multiple academic societies and related organizations (Japan Radiological Society, Society Radiation Oncology, Department EBM guidelines, Japan Council Quality Health Care (Minds), Pathology, patient group (NPO Patients Association)), in accordance Minds Manual Guideline Development (2020 ver. 3.0). The most...
To evaluate the clinical outcomes and histological types of renal cell carcinoma (RCC) arising in patients with end-stage disease (ESRD), to analyse relationship histopathological features duration dialysis.Clinical characteristics 34 who had a radical nephrectomy for RCC ESRD between November 1994 June 2008 were investigated. Archive paraffin-embedded tissue specimens obtained from 27 histochemically immunohistochemically analysed determine type.There was one death cancer patient local...
Lysophosphatidic acid (LPA) may enhance diverse biologic activities in prostate cancer. This study was conducted to analyze expression levels of LPA‐producing enzymes, autotaxin (ATX) and acylglycerol kinase (AGK), cancer with relevance clinicopathological parameters. Real‐time RT‐PCR western blotting were performed for ATX AGK non‐neoplastic cells (PrECs PrSCs) cell‐lines (DU‐145, PC‐3, LNCaP, AILNCaP). Immunohistochemical analyses tissue specimens 132 localized patients who underwent...
Active surveillance (AS) is one potential solution to avoiding the overtreatment of favorable prostate cancer. By handling AS strategy more safely, tumor aggressiveness may be evaluated accurately. The aim present study was evaluate predictive impact baseline prostate-specific antigen (PSA) isoform [-2]proPSA (p2PSA)-related indices on pathological reclassification at 1 year during an program.Between 2002 and 2003, 134 males diagnosed with low-risk cancer were registered in Japanese...
Abstract Metastatic burden is a critical factor for therapy decision‐making in metastatic hormone‐sensitive prostate cancer. The present study aimed to identify prognostic factors men with high‐ or low‐metastatic treated primary androgen‐deprivation therapy. included 2450 de novo cancer who were at 30 institutions across Japan between 2008 and 2017. We investigated the value of various clinicopathological parameters progression‐free survival (PFS) overall (OS) patients stratified by low‐...
The Paris System (TPS) for reporting urinary cytology differs from conventional systems (CS) in that it focuses on the diagnosis of high-grade urothelial carcinoma (HGUC). This study investigated impact TPS implementation diagnostic accuracy HGUC by comparing with our institutional CS.
The inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. predictive value of the presence a suspicious lesion at magnetic resonance imaging (MRI) time insufficiently known.To evaluate percentage patients needing treatment stratified by absence baseline MRI.A retrospective analysis data from multicentric AS GAP3 Consortium database was conducted. criteria were men with grade group (GG) 1 GG 2 cancer combined prostate-specific antigen <20 ng/ml. We...
5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis. We aimed to clarify the therapeutic benefits of orally administered diagnosis in transurethral resection non-muscle-invasive bladder cancer real-world setting. From January 2009 December 2020, patients with who have undergone visually complete by initial surgery were included. Histopathologically confirmed residual and intravesical recurrent was retrospectively investigated compared using conventional...
Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2 , as well treatment patterns and clinical outcomes, are not characterized among Japanese men mCRPC. Methods This multicenter, noninterventional cohort study enrolled mCRPC from 24 institutions between 2014 2018. Mutations the 15 HRR‐related genes were...
Abstract Objective To evaluate the real-world clinical usage and effectiveness of apalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods We retrospectively reviewed data 186 who received across 17 institutions. The primary outcomes were for nmCRPC: prior other androgen receptor signaling inhibitors (ARSIs), radical treatment, distribution prostate-specific antigen (PSA) doubling time (PSA-DT) at initial administration apalutamide. secondary efficacy...
Abstract Background Axitinib is a widely used tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma (mRCC) treatment. Here, we analyzed the characteristics of patients who did not respond to axitinib and evaluated alternative options for their Methods We retrospectively data 449 with mRCC were administered following another TKI as initial therapy. Patients progressive disease (PD) at first assessment defined showing early-PD. risk early-PD relationship between treatment...
TPS279 Background: PARP inhibitors (PARPi) in combination with androgen receptor pathway (ARPIs) are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARPi utilization earlier lines may result greater magnitude benefit. Saruparib is a potential best-in-class PARPi, which selectively inhibits and traps PARP1, has minimal effect on PARP2, hence offer an improved therapeutic window compared currently nonselective PARPi. The efficacy safety saruparib plus ARPIs...
358 Background: Recently, α2,3-sialylated prostate-specific antigen (S2,3PSA)% has been developed as a new serum biomarker for Prostate cancer (PCa). So, we aimed to investigate S2,3 PSA% predict reclassification of the first repeat protocol biopsy (1st re-PBx) on Active surveillance (AS) PCa patients. Methods: Patients who participated in PRIAS-JAPAN and its ancillary studies from August 2013 January 2022 met following criteria were included: clinical stage: T1c/T2, PSA: <10ng/ml, PSA...
351 Background: The current status of active surveillance (AS) for early-stage young Japanese patients is unknown. We examined it from the data PRIAS-JAPAN, a multicenter prospective collaborative study AS in Japan. Methods: Initially, low-risk with PSA density (PSAD) <0.2 and 2 or fewer positive cores were eligible. eligibility criteria have since been revised accordingly, 2021, when MRI imaging was performed, inclusion allowed PSAD up to 0.25, no upper limit on number Gleason score (GS)...
725 Background: First-line chemotherapy with 4-6 cycles followed by avelumab 1L maintenance therapy is the standard of care in patients metastatic urothelial carcinoma (mUC). However, a non-negligible number received less than four due to adverse events, or pre-existing severe comorbidities our daily practice. Thus, we examined prognostic impact first-line mUC treated avelumab. Methods: In this multi-institutional study, collected data 91 who following 1 st -line chemotherapy. Patients were...